183 related articles for article (PubMed ID: 27542210)
21. Functional studies of a novel germline p53 splicing mutation identified in a patient with Li-Fraumeni-like syndrome.
Piao J; Sakurai N; Iwamoto S; Nishioka J; Nakatani K; Komada Y; Mizutani S; Takagi M
Mol Carcinog; 2013 Oct; 52(10):770-6. PubMed ID: 22495821
[TBL] [Abstract][Full Text] [Related]
22. Super-Transactivation TP53 Variant in the Germline of a Family with Li-Fraumeni Syndrome.
Id Said B; Kim H; Tran J; Novokmet A; Malkin D
Hum Mutat; 2016 Sep; 37(9):889-92. PubMed ID: 27297285
[TBL] [Abstract][Full Text] [Related]
23. Allele-specific wild-type TP53 expression in the unaffected carrier parent of children with Li-Fraumeni syndrome.
Buzby JS; Williams SA; Schaffer L; Head SR; Nugent DJ
Cancer Genet; 2017 Feb; 211():9-17. PubMed ID: 28279309
[TBL] [Abstract][Full Text] [Related]
24. Germline TP53 mutations and Li-Fraumeni syndrome.
Varley JM
Hum Mutat; 2003 Mar; 21(3):313-20. PubMed ID: 12619118
[TBL] [Abstract][Full Text] [Related]
25. Reducing Fatty Acid Oxidation Improves Cancer-free Survival in a Mouse Model of Li-Fraumeni Syndrome.
Wang PY; Ma J; Li J; Starost MF; Wolfgang MJ; Singh K; Pirooznia M; Kang JG; Hwang PM
Cancer Prev Res (Phila); 2021 Jan; 14(1):31-40. PubMed ID: 32958587
[TBL] [Abstract][Full Text] [Related]
26. Aberrant p21WAF1-dependent growth arrest as the possible mechanism of abnormal resistance to ultraviolet light cytotoxicity in Li-Fraumeni syndrome fibroblast strains heterozygous for TP53 mutations.
Barley RD; Enns L; Paterson MC; Mirzayans R
Oncogene; 1998 Aug; 17(5):533-43. PubMed ID: 9704919
[TBL] [Abstract][Full Text] [Related]
27. Multiple primary tumors in a family with Li-Fraumeni syndrome with a TP53 germline mutation identified by next-generation sequencing.
Zampiga V; Danesi R; Tedaldi G; Tebaldi M; Cangini I; Pirini F; Pittureri C; Amaducci E; Guidi L; Faedi M; Amadori D; Falcini F; Calistri D
Int J Biol Markers; 2016 Dec; 31(4):e461-e465. PubMed ID: 27516001
[TBL] [Abstract][Full Text] [Related]
28. The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li-Fraumeni-like kindreds.
Siddiqui R; Onel K; Facio F; Nafa K; Diaz LR; Kauff N; Huang H; Robson M; Ellis N; Offit K
Fam Cancer; 2005; 4(2):177-81. PubMed ID: 15951970
[TBL] [Abstract][Full Text] [Related]
29. Functional characterization of novel germline TP53 variants in Swedish families.
Kharaziha P; Ceder S; Axell O; Krall M; Fotouhi O; Böhm S; Lain S; Borg Å; Larsson C; Wiman KG; Tham E; Bajalica-Lagercrantz S
Clin Genet; 2019 Sep; 96(3):216-225. PubMed ID: 31081129
[TBL] [Abstract][Full Text] [Related]
30. Mechanism of functional inactivation of a Li-Fraumeni syndrome p53 that has a mutation outside of the DNA-binding domain.
Gu J; Kawai H; Wiederschain D; Yuan ZM
Cancer Res; 2001 Feb; 61(4):1741-6. PubMed ID: 11245491
[TBL] [Abstract][Full Text] [Related]
31. Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers.
Bougeard G; Renaux-Petel M; Flaman JM; Charbonnier C; Fermey P; Belotti M; Gauthier-Villars M; Stoppa-Lyonnet D; Consolino E; Brugières L; Caron O; Benusiglio PR; Bressac-de Paillerets B; Bonadona V; Bonaïti-Pellié C; Tinat J; Baert-Desurmont S; Frebourg T
J Clin Oncol; 2015 Jul; 33(21):2345-52. PubMed ID: 26014290
[TBL] [Abstract][Full Text] [Related]
32. The Li-Fraumeni syndrome.
Chompret A
Biochimie; 2002 Jan; 84(1):75-82. PubMed ID: 11900879
[TBL] [Abstract][Full Text] [Related]
33. Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53.
Zhou R; Xu A; Gingold J; Strong LC; Zhao R; Lee DF
Trends Pharmacol Sci; 2017 Oct; 38(10):908-927. PubMed ID: 28818333
[TBL] [Abstract][Full Text] [Related]
34. Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome.
Shlien A; Tabori U; Marshall CR; Pienkowska M; Feuk L; Novokmet A; Nanda S; Druker H; Scherer SW; Malkin D
Proc Natl Acad Sci U S A; 2008 Aug; 105(32):11264-9. PubMed ID: 18685109
[TBL] [Abstract][Full Text] [Related]
35. Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome.
Kratz CP; Achatz MI; Brugières L; Frebourg T; Garber JE; Greer MC; Hansford JR; Janeway KA; Kohlmann WK; McGee R; Mullighan CG; Onel K; Pajtler KW; Pfister SM; Savage SA; Schiffman JD; Schneider KA; Strong LC; Evans DGR; Wasserman JD; Villani A; Malkin D
Clin Cancer Res; 2017 Jun; 23(11):e38-e45. PubMed ID: 28572266
[TBL] [Abstract][Full Text] [Related]
36. A novel germline TP53 mutation p.Pro190Arg detected in a patient with lung and bilateral breast cancers.
Krześniak M; Butkiewicz D; Rachtan J; Matuszczyk I; Grzybowska E; Rusin M
Adv Med Sci; 2017 Sep; 62(2):207-210. PubMed ID: 28499267
[TBL] [Abstract][Full Text] [Related]
37. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.
Achatz MI; Olivier M; Le Calvez F; Martel-Planche G; Lopes A; Rossi BM; Ashton-Prolla P; Giugliani R; Palmero EI; Vargas FR; Da Rocha JC; Vettore AL; Hainaut P
Cancer Lett; 2007 Jan; 245(1-2):96-102. PubMed ID: 16494995
[TBL] [Abstract][Full Text] [Related]
38. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL
Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139
[TBL] [Abstract][Full Text] [Related]
39. [Li-Fraumeni syndrome: update, new data and guidelines for clinical management].
Frebourg T; Abel A; Bonaiti-Pellie C; Brugières L; Berthet P; Bressac-de Paillerets B; Chevrier A; Chompret A; Cohen-Haguenauer O; Delattre O; Feingold J; Feunteun J; Frappaz D; Fricker JP; Gesta P; Jonveaux P; Kalifa C; Lasset C; Leheup B; Limacher JM; Longy M; Nogues C; Oppenheim D; Sommelet D; Soubrier F; Stoll C; Stoppa-Lyonnet D; Tristant H
Bull Cancer; 2001 Jun; 88(6):581-7. PubMed ID: 11459705
[TBL] [Abstract][Full Text] [Related]
40. Identification of a rare polymorphism in the human TP53 promoter.
Attwooll CL; McGown G; Thorncroft M; Stewart FJ; Birch JM; Varley JM
Cancer Genet Cytogenet; 2002 Jun; 135(2):165-72. PubMed ID: 12127401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]